>CONFERENCE CALL / WEBCAST
Palatin will host a conference call and webcast on May 14, 2012 at 11:00 a.m. Eastern time to discuss the results of operations in greater detail and an update on corporate developments. Individuals interested in listening to the conference call live can dial 1-888-264-8945 (domestic) or 1-913-312-0724 (international) pass code 8113465. The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com
. A telephone and webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 8113465. The webcast and telephone replay will be available through May 21, 2012.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical trials and clinical trial results, collaborations with others, potential collaborations or agreements on its product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE Palatin Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure2
. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 20083
. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 20084
. Palatin Technologies Receives Notification Letter from NYSE Alternext US5
. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 20096
. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US7
. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate8
. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration9
. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering10
. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference11
. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009